Harold Sy, MD
Cornea and External Diseases Specialist · Chicago, ILNPI 1992730030
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 28.3% of the total. 2025 is the largest year on record at $981, 3.3 times the $300 reported in 2019.
Across 180 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Glaukos Corporation$361
- Biotissue Holdings Inc.$335
- Alcon$304
- Sun Pharmaceutical Industries Inc.$243
- Mallinckrodt Hospital Products Inc.$209
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,841100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,085 |
| Glaukos Corporation | 6 | $361 |
| Biotissue Holdings Inc. | 15 | $335 |
| Alcon | 10 | $304 |
| Sun Pharmaceutical Industries Inc. | 5 | $243 |
| Mallinckrodt Hospital Products Inc. | 9 | $209 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $161 |
| Bausch & Lomb Americas Inc. | 8 | $151 |
| Novartis | 7 | $143 |
| Harrow Eye, LLC | 5 | $119 |
| Regeneron Healthcare Solutions, Inc. | 3 | $102 |
| Kala Pharmaceuticals, Inc. | 4 | $93 |
| Tarsus Pharmaceuticals, Inc. | 3 | $84 |
| Thea Pharma Inc. | 4 | $78 |
| Aerie Pharmaceuticals, Inc. | 4 | $76 |
| Amgen | 3 | $62 |
| Eyevance Pharmaceuticals LLC | 3 | $55 |
| Dompe US, Inc. | 2 | $44 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Rxsight Inc | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CE-marked KXLA system$179
- LUMIGAN$124
- DURYSTA$124
- XEN GLAUCOMA TREATMENT SYSTEM$124
- CEQUA$122
How this compares
Too few cornea and external diseases specialist providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $19,351 |
| LumiganBimatoprost | 49 | $16,118 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $11,398 |
| Prednisolone Acetate | 200 | $7,997 |
| Travoprost | 45 | $6,786 |
| Latanoprost | 607 | $5,883 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 79 | $3,964 |
| Ketorolac Tromethamine | 207 | $3,147 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $3,141 |
| MoxifloxacinMoxifloxacin Hcl | 127 | $2,626 |
| ErythromycinErythromycin Base | 210 | $2,273 |
| Brimonidine Tartrate | 86 | $2,142 |
| Timolol Maleate | 113 | $1,402 |
| Fluorometholone | 18 | $1,286 |
| Azelastine Hcl | 34 | $1,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,085 | $46,86794 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Chicago
- Nahrain SchumaierChicago$3K
- Andrea Arteaga UsecheChicago$2K
- Jennifer ParkChicago$881
- Avrey ThauChicago$502
- Raiza PerezChicago$236
- Farshad AbediChicago$145
- Hajirah SaeedChicago$37
- Rachel EpsteinHighland Park$6K
- Charles BouchardMaywood$4K
- Carter KirkRiver Forest$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.